1. Home
  2. RAVE vs CTSO Comparison

RAVE vs CTSO Comparison

Compare RAVE & CTSO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Rave Restaurant Group Inc.

RAVE

Rave Restaurant Group Inc.

N/A

Current Price

$2.65

Market Cap

40.1M

ML Signal

N/A

Logo Cytosorbents Corporation

CTSO

Cytosorbents Corporation

HOLD

Current Price

$0.63

Market Cap

45.7M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
RAVE
CTSO
Founded
1958
1997
Country
United States
United States
Employees
N/A
N/A
Industry
Restaurants
Medical/Dental Instruments
Sector
Consumer Discretionary
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
40.1M
45.7M
IPO Year
1995
2008

Fundamental Metrics

Financial Performance
Metric
RAVE
CTSO
Price
$2.65
$0.63
Analyst Decision
Buy
Analyst Count
0
2
Target Price
N/A
$5.38
AVG Volume (30 Days)
21.1K
69.0K
Earning Date
05-07-2026
03-25-2026
Dividend Yield
N/A
N/A
EPS Growth
11.76
N/A
EPS
0.09
N/A
Revenue
$15,120,000.00
$22,503,908.00
Revenue This Year
N/A
$7.29
Revenue Next Year
N/A
$8.91
P/E Ratio
$29.00
N/A
Revenue Growth
N/A
48.53
52 Week Low
$2.01
$0.60
52 Week High
$3.75
$1.39

Technical Indicators

Market Signals
Indicator
RAVE
CTSO
Relative Strength Index (RSI) 38.56 36.55
Support Level $2.34 $0.62
Resistance Level $3.21 $0.74
Average True Range (ATR) 0.13 0.06
MACD 0.00 -0.02
Stochastic Oscillator 48.65 10.23

Price Performance

Historical Comparison
RAVE
CTSO

About RAVE Rave Restaurant Group Inc.

Rave Restaurant Group Inc operates and franchises pizza buffet, delivery/carry-out, express restaurants, and ghost kitchens. It operates restaurants under the brand name, Pizza Inn, and Pie Five Pizza Company. It has three operating segments. The Pizza Inn Franchising and Pie Five Franchising segments establish franchisees, licensees, and territorial rights. The corporate administration and other segments. The Pizza Inn Franchising segment accounts for the majority of the company's revenue. Geographically, it generates the majority of the revenue from the United States.

About CTSO Cytosorbents Corporation

CytoSorbents Corp specializes in treating life-threatening conditions in intensive care and cardiac surgery using proprietary polymer adsorption technology. Its flagship product, CytoSorb, is approved in the EU as an extracorporeal cytokine absorber, aiming to reduce inflammation and prevent multiple organ failure in critical illnesses like sepsis and trauma. Revenue primarily comes from product sales in Germany, with additional income from grant agencies in the United States. The company operates through Direct sales and Distributors/strategic partners in United States, Germany and Other Countries. The company's product consists of Cytosorb, ECOS-300CY, VetResQ, HemoDefend, and DrugSorb-ATR.

Share on Social Networks: